trending Market Intelligence /marketintelligence/en/news-insights/trending/Y2B64vY_aWUEDIkS04El7Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Approvals for Roche, J&J; designations for AstraZeneca, ProQR Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Approvals for Roche, J&J; designations for AstraZeneca, ProQR Therapeutics

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Oct. 18.

Approvals

* Roche Holding AG's Xofluza for people at high risk of developing complications from influenza. Xofluza was previously approved to treat acute, uncomplicated influenza in people aged 12 years and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications.

* Johnson & Johnson and Bayer AG's Xarelto to prevent venous thromboembolism in acutely ill patients who are at risk of developing blood clot complications but are not at a high risk of bleeding.

* Amgen Inc.'s Nplate for newly diagnosed adults with immune thrombocytopenia, or ITP, and who have had an insufficient response to corticosteroids, immunoglobulins or surgery to remove the spleen. Nplate is already approved to treat ITP in adults and children aged one year and older.

* Hisamitsu Pharmaceutical Co. Inc. unit Noven Pharmaceuticals Inc.'s Secuado over-the-skin patch for adults with schizophrenia.

* Alkermes PLC and Biogen Inc.'s Vumerity for multiple sclerosis. The FDA granted tentative approval to the companies' application.

* Foamix Pharmaceuticals Ltd.'s Amzeeq for moderate to severe acne in patients aged nine years and older.

Extended review

* Flexion Therapeutics Inc.'s supplemental new drug application to revise the label of its osteoarthritis knee pain drug Zilretta. The Burlington, Mass.-based company said the FDA did not ask for new information.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Priority review

* AstraZeneca PLC and Daiichi Sankyo Co. Ltd.'s trastuzumab deruxtecan for breast cancer which has spread across the body and is human epidermal growth factor receptor 2-positive.

Other designations

* Rare pediatric disease designation, for ProQR Therapeutics NV's sepofarsen for Leber's congenital amaurosis 10.

* Orphan drug, for Neuren Pharmaceuticals Ltd.'s NNZ-2591 for Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome.